Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Recommendation of "Reduce" from Analysts

Key Points

• Analysts hold a bearish-to-neutral view: Integra LifeSciences has an average “Reduce” rating from eight analysts—two sells, five holds and one buy—with an average 12-month price target of $18.86.
• The stock recently traded at $15.06, below the analyst consensus target, with shares down 0.3% during the reported session. Its 52-week range is $8.70 to $20.49.
• Quarterly results exceeded expectations: Integra reported adjusted EPS of $0.56 versus the $0.48 consensus and revenue of $418.76 million, while institutional investors own approximately 84.78% of the stock.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) has received an average recommendation of "Reduce" from the eight analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $18.8571.

A number of equities research analysts have issued reports on the stock. Truist Financial increased their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a "hold" rating in a report on Thursday, July 16th. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating and set a $25.00 price target on the stock in a research note on Thursday, June 18th. Wells Fargo & Company increased their price objective on shares of Integra LifeSciences from $15.00 to $18.00 and gave the company an "equal weight" rating in a report on Thursday, July 30th. UBS Group assumed coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They set a "neutral" rating and a $19.00 price objective for the company. Finally, BMO Capital Markets began coverage on Integra LifeSciences in a report on Wednesday, July 8th. They issued a "market perform" rating and a $19.00 target price on the stock.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio acquired a new position in Integra LifeSciences in the 2nd quarter worth about $82,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Integra LifeSciences in the 2nd quarter worth $84,000. Sequoia Financial Advisors LLC raised its position in shares of Integra LifeSciences by 27.4% during the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company's stock valued at $134,000 after buying an additional 3,059 shares during the period. Amundi lifted its position in Integra LifeSciences by 80.8% in the first quarter. Amundi now owns 19,430 shares of the life sciences company's stock valued at $183,000 after buying an additional 8,681 shares during the last quarter. Finally, State of Wyoming lifted its stake in Integra LifeSciences by 26.4% during the first quarter. State of Wyoming now owns 25,276 shares of the life sciences company's stock worth $238,000 after purchasing an additional 5,278 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Down 0.3%

Shares of NASDAQ IART traded down $0.04 during mid-day trading on Friday, hitting $15.06. 107,242 shares of the stock traded hands, compared to its average volume of 874,916. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -167.20, a PEG ratio of 0.83 and a beta of 1.21. The stock has a fifty day moving average price of $17.41 and a 200-day moving average price of $14.73.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.08. The firm had revenue of $418.76 million for the quarter, compared to analysts' expectations of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Research analysts anticipate that Integra LifeSciences will post 2.46 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery and wound care. Its technologies are designed to help healthcare professionals treat complex conditions, repair damaged tissue and support surgical procedures.

The company's portfolio includes dural repair products and other neurosurgical implants, surgical instruments, regenerative tissue technologies, wound-care products and solutions for extremity reconstruction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.